Latest filing published 13 Apr 2020 for Avalo Therapeutics, Inc., €49k.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 3 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -24.1%Entry US$9,331.20 · Close at T+365 US$7,084.80
- -54.9%Entry US$15,465.60 · Close at T+365 US$6,969.60
- -0.3%Entry US$94,800.00 · Close at T+365 US$94,500.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Simon Pedder: trading record in brief
Simon Pedder is a declared insider at 4 companies; the most frequent names are Chelsea Therapeutics International, Ltd., Avalo Therapeutics, Inc. and Athenex, Inc. Over a trading history stretching from 23 August 2006 to 9 April 2020, the count stands at 14 filings.
No open-market sale appears; the market trades are 11 purchases worth €139k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 3 share grants.
Half of the purchases are above €7,054 and half below. 4 out of 4 purchases came within 30 days of a purchase by at least one other insider of the same company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. After 3 purchases with a full 90-day history, the hit rate stands at 33% and the median 90-day move at -14.9%. Past outcomes like these are no guarantee of what comes next.
Most recently, on 13 April 2020, the filings show a share grant worth €49k in Avalo Therapeutics, Inc. The last insider purchase was made public on 29 August 2019, 2,629 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Simon Pedder
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 20,901 shares@ US$2.57100.0% of flowCommon StockSEC:0001578563-20-000016:0
- 6,734 shares@ US$2.9819.2% of flowCommon StockSEC:0001578563-19-000025:0Canonical exit: 25 Nov 2019 (T+90)
- 250,000 shares0Common StockSEC:0001578563-19-000019:0
- 6,000 shares@ US$5.0628.7% of flowCommon StockSEC:0001578563-19-000016:0Canonical exit: 12 Aug 2019 (T+90)
- 1,402 shares0Common StockSEC:0001209191-19-024973:0
- 2,908 shares@ US$10.26100.0% of flowCommon StockSEC:0001209191-18-058608:0Canonical exit: 12 Feb 2019 (T+90)
- 1,000 shares@ US$11.0027.2% of flowCommon StockSEC:0000905148-17-000703:0Canonical exit: 17 Sept 2017 (T+90)
- 13,300 shares@ US$3.75Common Stock, par value $0.00001 per shareSEC:0001144204-14-052132:0Canonical exit: 18 Nov 2014 (T+90)
- 1,250 shares@ US$4.08Common StockSEC:0001181431-10-045686:0Canonical exit: 1 Dec 2010 (T+90)
- 4,600 shares@ US$2.20Common StockSEC:0001181431-09-057906:0Canonical exit: 17 Mar 2010 (T+90)
- 1,300 shares@ US$2.88Common StockSEC:0001181431-08-054351:0Canonical exit: 23 Dec 2008 (T+90)
- 200 shares@ US$2.89Common StockSEC:0001181431-08-054351:1Canonical exit: 23 Dec 2008 (T+90)
- 1,500 shares@ US$2.93Common StockSEC:0001181431-08-054351:2Canonical exit: 23 Dec 2008 (T+90)
- 1,000 shares@ US$3.27Common StockSEC:0001181431-06-049464:0Canonical exit: 21 Nov 2006 (T+90)
14 of 14 declarations
